GlassScriptPhysician profile
Brian S Galler
NPI 1629278833
$2,681.10
in general payments reported to CMS, 2019-2025
21 companies · $44.11 in 2025
The $44.11 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $50.72 · 2021: $691 · 2022: $135 · 2023: $550 · 2024: $224 · 2025: $44.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.08 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.17 | 2019-2025 | Jardiance |
| Amgen INC. | $311.76 | 2019 | |
| Boston Scientific Corporation | $301.85 | 2019-2023 | |
| Genzyme Corporation | $260.06 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $255.95 | 2019-2021 | |
| Edwards Lifesciences Corporation | $210.69 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $191.08 | 2019-2023 | Fasenra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.88 | 2019-2022 | |
| Relievant Medsystems, INC. | $140.81 | 2023 | Intracept |
| Regeneron Healthcare Solutions, INC. | $104.44 | 2024-2025 | Dupixent |
| Amarin Pharma, INC. | $91.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $69.40 | 2019-2021 | |
| Abbott Laboratories | $54.66 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $37.56 | 2019 | |
| Merck Sharp & Dohme LLC | $34.87 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $29.66 | 2021 | |
| Lundbeck LLC | $20.53 | 2019 | |
| Esperion Therapeutics, INC. | $19.71 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $18.69 | 2019 | |
| Vapotherm INC | $16.98 | 2021 | |
| Pfizer INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Galler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.